Astrazeneca shares fall as Crestor study backfires
Drug developer AstraZeneca’s has failed to establish that its best selling cholesterol fighter is better than Pfizer’s Lipitor. AstraZeneca PLC’s
Read more
Clinical Research Society
International Society for Clinical Research and Translational Medicine